AIM ImmunoTech (NYSE:AIM) Given New $1.00 Price Target at Maxim Group

AIM ImmunoTech (NYSE:AIM) had its target price dropped by equities researchers at Maxim Group from $2.00 to $1.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 284.76% from the company’s previous close.

Separately, Ascendiant Capital Markets decreased their price objective on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.

AIM ImmunoTech Trading Down 3.4 %

AIM opened at $0.26 on Tuesday. The company has a fifty day moving average price of $0.30 and a two-hundred day moving average price of $0.36. AIM ImmunoTech has a 1-year low of $0.21 and a 1-year high of $0.62. The company has a market cap of $13.38 million, a P/E ratio of -0.41 and a beta of -0.39. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.05.

AIM ImmunoTech (NYSE:AIM) last issued its earnings results on Wednesday, August 14th. The company reported ($0.03) EPS for the quarter. AIM ImmunoTech had a negative net margin of 13,952.74% and a negative return on equity of 269.04%. The firm had revenue of $0.05 million during the quarter. Analysts predict that AIM ImmunoTech will post -0.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC purchased a new stake in AIM ImmunoTech Inc. (NYSE:AIM) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent filing with the Securities and Exchange Commission. 12.02% of the stock is currently owned by institutional investors and hedge funds.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).